AnnJi Pharmaceutical Advances AJ201 to Pivotal Phase 3 Study for Spinal-Bulbar Muscular Atrophy

AnnJi Pharmaceutical has initiated the ROMA-KD pivotal phase 3 study for its investigational therapy AJ201, targeting spinal-bulbar muscular atrophy (SBMA). This marks a significant advancement, positioning AJ201 as the sole therapy for SBMA in phase 3 clinical development worldwide.

AJ201, also known as rosolutamide, is an orally administered small molecule designed to target the androgen receptor. Dysregulation of the androgen receptor pathway is implicated in the pathogenesis of SBMA, a rare and progressive neurodegenerative disease.

The ROMA-KD study is a crucial step in evaluating AJ201's efficacy and safety profile. The drug aims to potentially slow disease progression and alleviate symptoms associated with SBMA, a condition that affects motor neurons and leads to significant muscle weakness.

This phase 3 trial follows previous studies that have demonstrated AJ201's safety and tolerability. The outcomes of the ROMA-KD study will be critical for determining the future regulatory pathway for AJ201 and its potential to become a treatment option for patients suffering from SBMA.